Physicochemical characterization and phase I study of CMAB008, an infliximab biosimilar produced by a different expression system

BACKGROUND: Infliximab (Remicade), a chimeric monoclonal antibody against human TNFα, will inevitably face competition from biosimilar products, because of its effectiveness in autoimmune diseases and rapidly increasing market demand. According to guidelines for biosimilar development, the “biosimil...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Drug Des Devel Ther
Hoofdauteurs: An, Qing, Zheng, Yingxin, Zhao, Yirong, Liu, Tao, Guo, Huaizu, Zhang, Dapeng, Qian, Weizhu, Wang, Hao, Guo, Yajun, Hou, Sheng, Li, Jing
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Dove Medical Press 2019
Onderwerpen:
Clinical Trial Report
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6420106/
https://ncbi.nlm.nih.gov/pubmed/30880912
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S170913
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items